A New Frontier in Autoimmune Treatment
CAR-T cell therapy is beginning to redefine how we think about autoimmune and rheumatic diseases.
What started as a breakthrough in cancer treatment is now showing the potential to reset the immune system in patients with severe, treatment-resistant conditions.
For patients with diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, and other complex autoimmune disorders, early results suggest that CAR-T therapy may achieve deep and sustained remission—even after multiple therapies have failed.
What Is CAR-T Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an advanced form of immunotherapy that uses the patient’s own immune cells. T cells are collected from the patient and genetically modified to target specific cells—in this case, the B cells that play a central role in many autoimmune diseases. These engineered cells are then expanded and infused back into the patient, where they eliminate the malfunctioning immune cells and allow the immune system to rebuild in a more balanced way.
While CAR-T has been widely used in oncology, its application in autoimmune diseases is more recent but rapidly evolving. To date, approximately 300 patients worldwide have been treated with CAR-T therapy for autoimmune diseases, with growing clinical experience and encouraging outcomes.
Which Rheumatic Diseases Are Being Treated?
CAR-T therapy is currently being explored for several severe autoimmune and rheumatic conditions, including:
- Systemic Lupus Erythematosus - Lupus (SLE)
- Rheumatoid Arthritis
- Systemic Sclerosis (Scleroderma)
- Sjögren’s Syndrome
- Vasculitis (ANCA-associated)
- Myositis
- Dermatomyositis
Most patients treated so far had disease that did not respond to conventional therapies, including biologics.
Potential Side Effects
As with its use in oncology, CAR-T therapy for autoimmune diseases can involve side effects that require careful monitoring.
The most common include:
- Cytokine Release Syndrome (CRS) – typically milder in autoimmune indications compared to cancer
- Temporary immune suppression
- Increased risk of infection
- Transient neurological symptoms (rare)
Overall, early data suggest that the safety profile in autoimmune diseases may be more manageable, but treatment should still be performed in experienced centers.
Availability Worldwide
CAR-T therapy for autoimmune and rheumatic diseases is still in the early stages of clinical adoption.
Currently, access is limited and typically available through:
- Clinical trials
- Specialized academic centers
- Selected programs with early clinical experience
Unlike CAR-T for blood cancers, this indication is not yet widely approved in most countries. However, the field is progressing quickly, and more centers are beginning to offer treatment under structured protocols.
For international patients, access often requires careful coordination, medical evaluation, and timing.
Conclusion
CAR-T therapy represents a promising new approach for patients with severe autoimmune and rheumatic diseases.
By targeting the underlying immune dysfunction, it offers the possibility of long-term remission rather than ongoing disease control.
While still an emerging field, early results are highly encouraging, and ongoing research is expected to expand both availability and indications in the coming years.
Publication date: March 2026
